User banner image
User avatar
  • admin

Posts

Ascentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in CML-CP at ASCO 2026

ROCKVILLE, Md. and SUZHOU, China, May 31, 2026 (GLOBE NEWSWIRE) — Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company...

Precede Biosciences Presents New ASCO 2026 Data Demonstrating Ability of Precede Bio Insight™ to Decode MET-Driven Biology and Resistance in Advanced NSCLC

Data include assessment of MET expression, tumor and immune pathway activity, and lineage plasticity from just 1 mL of plasma in advanced NSCLC Plasma MET...

United Imaging Spotlights Molecular Imaging Showstoppers at SNMMI 2026

LOS ANGELES, May 31, 2026 /PRNewswire/ — United Imaging, a global innovator in AI-powered advanced medical imaging technologies and intelligent healthcare solutions, is presenting its...

BLUETTI Launches EOFY Sale on Power Solutions with Up to 44% OFF

SYDNEY, June 1, 2026 /PRNewswire/ — Clean energy leader BLUETTI is unleashing massive EOFY deals during June 1–30, up to 44% off its diverse portable...

HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to Be Presented at ASCO 2026 Plenary Session

CHICAGO, May 31, 2026 /PRNewswire/ — Akeso, Inc. (9926.HK) (“Akeso” or the “Company”) today announced that ivonescimab, the Company’s first-in-class PD-1/VEGF bispecific antibody, has achieved...

Relief as Firmable locates 15,000 accounting decision-makers reported missing at leading global B2B data provider

Sydney-based sales team initiates platform support ticket after discovering significantly more contacts than expected. Investigation concludes that data is correct. MELBOURNE, Australia and SINGAPORE, May...

Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma

Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma Brenetafusp monotherapy resulted in a 6-month overall survival rate of...

Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

WOBURN, Mass., May 31, 2026 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today...

SlimTide Truth Revealed (2026 Official Website Risk Warning) Avoid Hidden Fees & Fake Complaints

SlimTide Prebiotic Probiotic Formula for Gut Health and Metabolic Support: Ingredients, Side Effects, Dosage, and 60-Day Guarantee Breakdown Largo, FL, May 31, 2026 (GLOBE NEWSWIRE)...

NeuExcell Therapeutics Announces Encouraging Data of NXL-004 in Recurrent Malignant Glioma at 2026 ASCO

CHICAGO, May 31, 2026 (GLOBE NEWSWIRE) — NeuExcell Therapeutics today announced that Dr. Yulun Huang will present the first-in-human clinical study of NXL-004 for recurrent...